The accuracy of the trifocal IOL calculation using equivalent K-readings and total corneal power in different zones.

PURPOSE: To identify the equivalent K-readings and total keratometry zones that is optimally suitable for calculating the IOL spheroequivalent according to 7 formulas. METHODS: The study included 40 patients (40 eyes) who underwent uneventful femtosecond laser-assisted cataract surgery and refractive lens exchange (RLE) with implantation of a trifocal diffractive IOL (PanOptix, Alcon inc.). Targeted emmetropia was achieved in all patients, no distance and near correction was needed. Retrospective IOL calculations were performed utilizing 7 formulas (SRK/T, Holladay 1 and 2, Haigis, Hoffer Q, Barrett Universal 2, Olsen) and Pentacam keratometry data: Holladay equivalent K-readings, total optical power by ray tracing (TCRP) centered on the apex and pupil in 10 zones (from 0.5 to 5 mm in 0.5 mm increments). For each formula/zone/map combination: postoperative predicted refraction (PPRs), mean absolute errors (MAEs), and median absolute errors (MedAEs) were analyzed. RESULTS: According to EKR, the Haigis formula showed the lowest error in the central zones up to 3.5 mm, the TCRP zone for Holladay I and II formulas 4.0-4.5 mm, for HofferQ and SRK/T formulas 4.5-5.0 mm, and for Olsen and Barrett II Universal-5 mm. CONCLUSION: The use of keratometry data (EKR, TCRP) in the formulas adapted to SimK, with the correct choice of the evaluation zone of keratometric data, will increase the chance of hitting the refractive target.

Inhibition of ERK1/2 signaling prevents epileptiform behavior in rats prone to audiogenic seizures.

It has recently been proposed that extracellular signal-regulated kinases 1 and 2 (ERK1/2) are one of the factors mediating seizure development. We hypothesized that inhibition of ERK1/2 activity could prevent audiogenic seizures by altering GABA and glutamate release mechanisms. Krushinsky-Molodkina rats, genetically prone to audiogenic seizure, were recruited in the experiments. Animals were i.p. injected with an inhibitor of ERK1/2 SL 327 at different doses 60 min before audio stimulation. We demonstrated for the first time that inhibition of ERK1/2 activity by SL 327 injections prevented seizure behavior and this effect was dose-dependent and correlated with ERK1/2 activity. The obtained data also demonstrated unchanged levels of GABA production, and an increase in the level of vesicular glutamate transporter 2. The study of exocytosis protein expression showed that SL 327 treatment leads to downregulation of vesicle-associated membrane protein 2 and synapsin I, and accumulation of synaptosomal-associated protein 25 (SNAP-25). The obtained data indicate that the inhibition of ERK1/2 blocks seizure behavior presumably by altering the exocytosis machinery, and identifies ERK1/2 as a potential target for the development of new strategies for seizure treatment. Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are one of the factors mediating seizure development. Here we report that inhibition of ERK1/2 by SL 327 prevented seizure behavior and this effect was dose-dependent and correlated with ERK1/2 activity. Accumulation of VGLUT2 was associated with differential changing of synaptic proteins VAMP2, SNAP-25 and synapsin I. The obtained data indicate that the inhibition of ERK1/2 alters neurotransmitter release by changing the exocytosis machinery, thus preventing seizures.

Using the CER Hub to ensure data quality in a multi-institution smoking cessation study.

Comparative effectiveness research (CER) studies involving multiple institutions with diverse electronic health records (EHRs) depend on high quality data. To ensure uniformity of data derived from different EHR systems and implementations, the CER Hub informatics platform developed a quality assurance (QA) process using tools and data formats available through the CER Hub. The QA process, implemented here in a study of smoking cessation services in primary care, used the 'emrAdapter' tool programmed with a set of quality checks to query large samples of primary care encounter records extracted in accord with the CER Hub common data framework. The tool, deployed to each study site, generated error reports indicating data problems to be fixed locally and aggregate data sharable with the central site for quality review. Across the CER Hub network of six health systems, data completeness and correctness issues were prevalent in the first iteration and were considerably improved after three iterations of the QA process. A common issue encountered was incomplete mapping of local EHR data values to those defined by the common data framework. A highly automated and distributed QA process helped to ensure the correctness and completeness of patient care data extracted from EHRs for a multi-institution CER study in smoking cessation.

Results and outcome reporting In ClinicalTrials.gov, what makes it happen?

BACKGROUND: At the end of the past century there were multiple concerns regarding lack of transparency in the conduct of clinical trials as well as some ethical and scientific issues affecting the trials' design and reporting. In 2000 ClinicalTrials.gov data repository was developed and deployed to serve public and scientific communities with valid data on clinical trials. Later in order to increase deposited data completeness and transparency of medical research a set of restrains had been imposed making the results deposition compulsory for multiple cases. METHODS: We investigated efficiency of the results deposition and outcome reporting as well as what factors make positive impact on providing information of interest and what makes it more difficult, whether efficiency depends on what kind of institution was a trial sponsor. Data from the ClinicalTrials.gov repository has been classified based on what kind of institution a trial sponsor was. The odds ratio was calculated for results and outcome reporting by different sponsors' class. RESULTS: As of 01/01/2012 118,602 clinical trials data deposits were made to the depository. They came from 9068 different sources. 35344 (29.8%) of them are assigned as FDA regulated and 25151 (21.2%) as Section 801 controlled substances. Despite multiple regulatory requirements, only about 35% of trials had clinical study results deposited, the maximum 55.56% of trials with the results, was observed for trials completed in 2008. CONCLUSIONS: The most positive impact on depositing results, the imposed restrains made for hospitals and clinics. Health care companies showed much higher efficiency than other investigated classes both in higher fraction of trials with results and in providing at least one outcome for their trials. They also more often than others deposit results when it is not strictly required, particularly, in the case of non-interventional studies.

The structure of lombricine kinase: implications for phosphagen kinase conformational changes.

Lombricine kinase is a member of the phosphagen kinase family and a homolog of creatine and arginine kinases, enzymes responsible for buffering cellular ATP levels. Structures of lombricine kinase from the marine worm Urechis caupo were determined by x-ray crystallography. One form was crystallized as a nucleotide complex, and the other was substrate-free. The two structures are similar to each other and more similar to the substrate-free forms of homologs than to the substrate-bound forms of the other phosphagen kinases. Active site specificity loop 309-317, which is disordered in substrate-free structures of homologs and is known from the NMR of arginine kinase to be inherently dynamic, is resolved in both lombricine kinase structures, providing an improved basis for understanding the loop dynamics. Phosphagen kinases undergo a segmented closing on substrate binding, but the lombricine kinase ADP complex is in the open form more typical of substrate-free homologs. Through a comparison with prior complexes of intermediate structure, a correlation was revealed between the overall enzyme conformation and the substrate interactions of His(178). Comparative modeling provides a rationale for the more relaxed specificity of these kinases, of which the natural substrates are among the largest of the phosphagen substrates.

Subunit dissociation and metal binding by Escherichia coli apo-manganese superoxide dismutase.

Metal binding by apo-manganese superoxide dismutase (apo-MnSOD) is essential for functional maturation of the enzyme. Previous studies have demonstrated that metal binding by apo-MnSOD is conformationally gated, requiring protein reorganization for the metal to bind. We have now solved the X-ray crystal structure of apo-MnSOD at 1.9Å resolution. The organization of active site residues is independent of the presence of the metal cofactor, demonstrating that protein itself templates the unusual metal coordination geometry. Electrophoretic analysis of mixtures of apo- and (Mn2)-MnSOD, dye-conjugated protein, or C-terminal Strep-tag II fusion protein reveals a dynamic subunit exchange process associated with cooperative metal binding by the two subunits of the dimeric protein. In contrast, (S126C) (SS) apo-MnSOD, which contains an inter-subunit covalent disulfide-crosslink, exhibits anti-cooperative metal binding. The protein concentration dependence of metal uptake kinetics implies that protein dissociation is involved in metal binding by the wild type apo-protein, although other processes may also contribute to gating metal uptake. Protein concentration dependent small-zone size exclusion chromatography is consistent with apo-MnSOD dimer dissociation at low protein concentration (K(D)=1×10⁻5 M). Studies on metal uptake by apo-MnSOD in Escherichia coli cells show that the protein exhibits similar behavior in vivo and in vitro.

The crystal structure of the AF2331 protein from Archaeoglobus fulgidus DSM 4304 forms an unusual interdigitated dimer with a new type of alpha + beta fold.

The structure of AF2331, a 11-kDa orphan protein of unknown function from Archaeoglobus fulgidus, was solved by Se-Met MAD to 2.4 A resolution. The structure consists of an alpha + beta fold formed by an unusual homodimer, where the two core beta-sheets are interdigitated, containing strands alternating from both subunits. The decrease in solvent-accessible surface area upon dimerization is unusually large (3960 A(2)) for a protein of its size. The percentage of the total surface area buried in the interface (41.1%) is one of the largest observed in a nonredundant set of homodimers in the PDB and is above the mean for nearly all other types of homo-oligomers. AF2331 has no sequence homologs, and no structure similar to AF2331 could be found in the PDB using the CE, TM-align, DALI, or SSM packages. The protein has been identified in Pfam 23.0 as the archetype of a new superfamily and is topologically dissimilar to all other proteins with the "3-Layer (BBA) Sandwich" fold in CATH. Therefore, we propose that AF2331 forms a novel alpha + beta fold. AF2331 contains multiple negatively charged surface clusters and is located on the same operon as the basic protein AF2330. We hypothesize that AF2331 and AF2330 may form a charge-stabilized complex in vivo, though the role of the negatively charged surface clusters is not clear.

Benefits of structural genomics for drug discovery research.

While three dimensional structures have long been used to search for new drug targets, only a fraction of new drugs coming to the market has been developed with the use of a structure-based drug discovery approach. However, the recent years have brought not only an avalanche of new macromolecular structures, but also significant advances in the protein structure determination methodology only now making their way into structure-based drug discovery. In this paper, we review recent developments resulting from the Structural Genomics (SG) programs, focusing on the methods and results most likely to improve our understanding of the molecular foundation of human diseases. SG programs have been around for almost a decade, and in that time, have contributed a significant part of the structural coverage of both the genomes of pathogens causing infectious diseases and structurally uncharacterized biological processes in general. Perhaps most importantly, SG programs have developed new methodology at all steps of the structure determination process, not only to determine new structures highly efficiently, but also to screen protein/ligand interactions. We describe the methodologies, experience and technologies developed by SG, which range from improvements to cloning protocols to improved procedures for crystallographic structure solution that may be applied in "traditional" structural biology laboratories particularly those performing drug discovery. We also discuss the conditions that must be met to convert the present high-throughput structure determination pipeline into a high-output structure-based drug discovery system.

An extremely SAD case: structure of a putative redox-enzyme maturation protein from Archaeoglobus fulgidus at 3.4 A resolution.

This paper describes the crystal structure of AF0173, a putative redox-enzyme maturation protein (REMP) from Archaeoglobus fulgidus. The REMPs serve as chaperones in the maturation of extracytoplasmic oxidoreductases in archaea and bacteria. The all-helical subunits of AF0173 form a dimer arising from the interaction of residues located in a funnel-shaped cavity on one subunit surface with an uncut expression tag from the other subunit. This cavity is likely to represent a binding site for the twin-arginine motif that interacts with REMPs. The conservation of the overall fold in AF0173 and bacterial REMPs as well as the presence of conserved residues in their putative binding sites indicates that REMPs act in a similar manner in archaea and bacteria despite their limited sequence similarity. A model of the binding of the twin-arginine motif by AF0173 is suggested. The solution of the AF0173 structure by the single anomalous dispersion method represents an extreme case of SAD structure determination: low resolution (3.4 A), the absence of NCS and the presence of only two anomalously scattering atoms in the asymmetric unit. An unusually high solvent content (73%) turned out to be important for the success of the density-modification procedures.

Map2mod--a server for evaluation of crystallographic models and their agreement with electron density maps.

Here we report on recent developments of the map2mod server. It has been designed for validation of protein models created by X-ray data interpretation. It can also be used during the refinement process since it is able to indicate problem regions in the model. Apart from evaluation of model quality, it has an option to remove atoms of side chains, which are not consistent with the maps as well as improperly placed water molecules. There are two additional options: checking the B-factors of atoms in the provided model and comparison of R and R(free) values obtained as the result of refinement with the averages characteristic for the data resolution shell.

Breaking good resolutions with ARP/wARP.

New procedures are outlined that enable ARP/wARP to automatically build protein models with diffraction data extending to about 2.5 A. An overview of ongoing research is given and possible future advances are discussed.

Functional morphology of ductus venosus in human fetus.

OBJECTIVES: The morphology of region umbilical vein, umbilical sinus and ductus venosus of human fetuses have been investigated. MATERIAL AND METHODS: 26 human fetuses between 20 and 40 weeks' gestation were examined by morphological methods. The umbilical vein, DV and the portal vein were obtained after termination of gestation. Tissue samples have been fixed in phormaldehyde solution (pH 7,2) and were embedded in paraffin. The paraffin sections (5-7 micro k) were stained with hematoxylin and eosin, silver impregnation by Bilchovski, orcein, pikrofuchsin. Measurement of the angle between ductus venosus and the portal vein was obtained with alidade. RESULTS: Anatomical scheme of the region of umbilical vein, umbilical sinus and DV indicating two different patterns. The first: DV has situated into line with umbilical vein (22 cases). The second: umbilical vein has rotated before umbilical sinus, forming the turn in right (4 cases). The double-layer wall of ductus venosus (DV) contained the elastic, collagen and argyrophilic fibers. Around isthmus region of DV vasa vasorum and nervi vasorum have been found. The specific anatomical finding of the ductal isthmus was an accumulation of smooth muscle cells as intimal pillow, which were protruded into the vascular lumen. The double-layer wall of portal sinus (intima and adventitia) have been as the internal elastic membrane. The smooth muscle cells have been revealed in the walls, were not formed the tunica media at term 20-40 weeks of gestation. By the contrast the umbilical vein showed multiple, circularly running smooth muscle bundles. In this study, the ductal thickness was consistently bigger in the inlet than in the outlet. The tunica adventitia was greatest in the junction with the portal sinus and the inferior vena cava compared with the part arranged in the liver parenchyma. The wall thickness of the portal sinus and of the umbilical vein was significantly higher than of the duclal wall. CONCLUSION: The vascular muscle-elastic cells of intimal hyperplasia ("intimal pillow") in wall of DV, probably, executes the role of the fortification of resistant behaviours of vessel wall in connection with DV and portal sinus with high hemodynamics load in this area. The maximum thickness of adventicia in the field of joints also witnesses an hemodynamic in favour of particularities. The angle between DV and left branches of portal vein in dominate cases was sharp and right that reflects the general regularity of architectonics of the vascular riverbed.